Latest metastatic pancreatic cancer Stories
Recent FDA meeting allows for potential marketing application based on progression free survival in pivotal Phase 3 pancreatic cancer study SAN DIEGO, April 8, 2015 /PRNewswire/ -- Halozyme
- ABRAXANE plus gemcitabine to be PBS listed for Australian patients with metastatic pancreatic cancer from 1 November MELBOURNE, Australia, Oct.
High unmet need addressed with first new approved treatment in eighteen years MISSISSAUGA, ON, August 6, 2014 /CNW/ - Health Canada has approved (Pr)ABRAXANE(®)
CALGARY, July 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc.
-- ABRAXANE plus gemcitabine approved by the TGA for the first-line treatment of metastatic pancreatic cancer MELBOURNE, Australia, March 18, 2014 /PRNewswire/ -- Australian biopharmaceutical
DEERFIELD, Ill., June 6, 2011 /PRNewswire/ -- Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc.